-
Je něco špatně v tomto záznamu ?
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
T. Tamura, J. Ito, K. Uriu, J. Zahradnik, I. Kida, Y. Anraku, H. Nasser, M. Shofa, Y. Oda, S. Lytras, N. Nao, Y. Itakura, S. Deguchi, R. Suzuki, L. Wang, MM. Begum, S. Kita, H. Yajima, J. Sasaki, K. Sasaki-Tabata, R. Shimizu, M. Tsuda, Y. Kosugi,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2015
Free Medical Journals
od 2010
Nature Open Access
od 2010-12-01
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2010-01-01
Open Access Digital Library
od 2015-01-01
Open Access Digital Library
od 2015-01-01
Medline Complete (EBSCOhost)
od 2012-11-01
Health & Medicine (ProQuest)
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
Springer Nature OA/Free Journals
od 2010-12-01
- MeSH
- COVID-19 * MeSH
- fylogeneze MeSH
- glykoprotein S, koronavirus genetika MeSH
- křečci praví MeSH
- lidé MeSH
- rekombinace genetická MeSH
- SARS-CoV-2 genetika MeSH
- zvířata MeSH
- Check Tag
- křečci praví MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.
1st Medical Faculty at Biocev Charles University Vestec Prague Czechia
AMED CREST Japan Agency for Medical Research and Development Tokyo Japan
Center for Animal Disease Control University of Miyazaki Miyazaki Japan
Center for iPS Cell Research and Application Kyoto University Kyoto Japan
CREST Japan Science and Technology Agency Kawaguchi Japan
Department of Biomolecular Sciences Weizmann Institute of Science Rehovot Israel
Department of Cancer Pathology Faculty of Medicine Hokkaido University Sapporo Japan
Department of Clinical Pathology Faculty of Medicine Suez Canal University Ismailia Egypt
Department of Microbiology and Immunology Faculty of Medicine Hokkaido University Sapporo Japan
Department of Veterinary Science Faculty of Agriculture University of Miyazaki Miyazaki Japan
Global Station for Biosurfaces and Drug Discovery Hokkaido University Sapporo Japan
Graduate School of Frontier Sciences The University of Tokyo Kashiwa Japan
Graduate School of Medicine and Veterinary Medicine University of Miyazaki Miyazaki Japan
Graduate School of Medicine The University of Tokyo Tokyo Japan
Institute for Chemical Reaction Design and Discovery Hokkaido University Sapporo Japan
Institute for Genetic Medicine Hokkaido University Sapporo Japan
Institute for Vaccine Research and Development HU IVReD Hokkaido University Sapporo Japan
Laboratory of Medical Virology Institute for Life and Medical Sciences Kyoto University Kyoto Japan
Laboratory of Virus Control Research Institute for Microbial Diseases Osaka University Suita Japan
Medical Research Council University of Glasgow Centre for Virus Research Glasgow UK
One Health Research Center Hokkaido University Sapporo Japan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011428
- 003
- CZ-PrNML
- 005
- 20230801133034.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41467-023-38435-3 $2 doi
- 035 __
- $a (PubMed)37193706
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tamura, Tomokazu $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000313956610
- 245 10
- $a Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants / $c T. Tamura, J. Ito, K. Uriu, J. Zahradnik, I. Kida, Y. Anraku, H. Nasser, M. Shofa, Y. Oda, S. Lytras, N. Nao, Y. Itakura, S. Deguchi, R. Suzuki, L. Wang, MM. Begum, S. Kita, H. Yajima, J. Sasaki, K. Sasaki-Tabata, R. Shimizu, M. Tsuda, Y. Kosugi, S. Fujita, L. Pan, D. Sauter, K. Yoshimatsu, S. Suzuki, H. Asakura, M. Nagashima, K. Sadamasu, K. Yoshimura, Y. Yamamoto, T. Nagamoto, G. Schreiber, K. Maenaka, Genotype to Phenotype Japan (G2P-Japan) Consortium, T. Hashiguchi, T. Ikeda, T. Fukuhara, A. Saito, S. Tanaka, K. Matsuno, K. Takayama, K. Sato
- 520 9_
- $a In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a křečci praví $7 D006224
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a fylogeneze $7 D010802
- 650 _2
- $a SARS-CoV-2 $x genetika $7 D000086402
- 650 _2
- $a rekombinace genetická $7 D011995
- 650 _2
- $a glykoprotein S, koronavirus $x genetika $7 D064370
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ito, Jumpei $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $1 https://orcid.org/0000000304408321
- 700 1_
- $a Uriu, Keiya $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Zahradnik, Jiri $u Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel $u First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia $1 https://orcid.org/0000000286984236
- 700 1_
- $a Kida, Izumi $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000263121454
- 700 1_
- $a Anraku, Yuki $u Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000257310902
- 700 1_
- $a Nasser, Hesham $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan $u Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt $1 https://orcid.org/0000000191631665
- 700 1_
- $a Shofa, Maya $u Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan $u Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan
- 700 1_
- $a Oda, Yoshitaka $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Lytras, Spyros $u Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, UK $1 https://orcid.org/0000000342026682
- 700 1_
- $a Nao, Naganori $u Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan $u One Health Research Center, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Itakura, Yukari $u Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan $u Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000234631834
- 700 1_
- $a Deguchi, Sayaka $u Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- 700 1_
- $a Suzuki, Rigel $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Wang, Lei $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan $1 https://orcid.org/000000016145395X
- 700 1_
- $a Begum, Mst Monira $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan
- 700 1_
- $a Kita, Shunsuke $u Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan $1 https://orcid.org/000000033969302X
- 700 1_
- $a Yajima, Hisano $u Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan
- 700 1_
- $a Sasaki, Jiei $u Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan
- 700 1_
- $a Sasaki-Tabata, Kaori $u Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
- 700 1_
- $a Shimizu, Ryo $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan
- 700 1_
- $a Tsuda, Masumi $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000154005905
- 700 1_
- $a Kosugi, Yusuke $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Fujita, Shigeru $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Medicine, The University of Tokyo, Tokyo, Japan $1 https://orcid.org/0000000190082123
- 700 1_
- $a Pan, Lin $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
- 700 1_
- $a Sauter, Daniel $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan $u Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany $1 https://orcid.org/0000000176650040
- 700 1_
- $a Yoshimatsu, Kumiko $u Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000200622753
- 700 1_
- $a Suzuki, Saori $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan $1 https://orcid.org/0000000152336604
- 700 1_
- $a Asakura, Hiroyuki $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Nagashima, Mami $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Sadamasu, Kenji $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Yoshimura, Kazuhisa $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Yamamoto, Yuki $u HiLung, Inc., Kyoto, Japan
- 700 1_
- $a Nagamoto, Tetsuharu $u HiLung, Inc., Kyoto, Japan
- 700 1_
- $a Schreiber, Gideon $u Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel $1 https://orcid.org/0000000229225882
- 700 1_
- $a Maenaka, Katsumi $u Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan $u Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan $u Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan $u Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan $1 https://orcid.org/000000025459521X
- 700 1_
- $a Hashiguchi, Takao $u Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan $u CREST, Japan Science and Technology Agency, Kawaguchi, Japan $1 https://orcid.org/0000000175787571
- 700 1_
- $a Ikeda, Terumasa $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan $1 https://orcid.org/0000000328699450
- 700 1_
- $a Fukuhara, Takasuke $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan $u Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan $u AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan $u Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Japan $1 https://orcid.org/0000000154718331
- 700 1_
- $a Saito, Akatsuki $u Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan $u Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan $u Center for Animal Disease Control, University of Miyazaki, Miyazaki, Japan $1 https://orcid.org/0000000227924399
- 700 1_
- $a Tanaka, Shinya $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. tanaka@med.hokudai.ac.jp $u Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. tanaka@med.hokudai.ac.jp $1 https://orcid.org/0000000164703301
- 700 1_
- $a Matsuno, Keita $u Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan. matsuk@czc.hokudai.ac.jp $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan. matsuk@czc.hokudai.ac.jp $u One Health Research Center, Hokkaido University, Sapporo, Japan. matsuk@czc.hokudai.ac.jp $u International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan. matsuk@czc.hokudai.ac.jp $1 https://orcid.org/0000000242056526
- 700 1_
- $a Takayama, Kazuo $u Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. kazuo.takayama@cira.kyoto-u.ac.jp $u CREST, Japan Science and Technology Agency, Kawaguchi, Japan. kazuo.takayama@cira.kyoto-u.ac.jp
- 700 1_
- $a Sato, Kei $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. KeiSato@g.ecc.u-tokyo.ac.jp $u Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. KeiSato@g.ecc.u-tokyo.ac.jp $u Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan. KeiSato@g.ecc.u-tokyo.ac.jp $u CREST, Japan Science and Technology Agency, Kawaguchi, Japan. KeiSato@g.ecc.u-tokyo.ac.jp $u International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. KeiSato@g.ecc.u-tokyo.ac.jp $u International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. KeiSato@g.ecc.u-tokyo.ac.jp $u Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan. KeiSato@g.ecc.u-tokyo.ac.jp $1 https://orcid.org/0000000344311380
- 710 2_
- $a Genotype to Phenotype Japan (G2P-Japan) Consortium
- 773 0_
- $w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 14, č. 1 (2023), s. 2800
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37193706 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801133031 $b ABA008
- 999 __
- $a ok $b bmc $g 1963690 $s 1197693
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 14 $c 1 $d 2800 $e 20230516 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
- LZP __
- $a Pubmed-20230718
